Skip to main content

Table 1 Demographic data of evaluable NMOSD and MS patients during the follow-up period

From: Comparison between the cranial magnetic resonance imaging features of neuromyelitis optica spectrum disorder versus multiple sclerosis in Taiwanese patients

 

NMOSD (n = 25)

MS (n = 29)

P -value

Age at 1st attack (years old)

37.8 ± 13.6

33.7 ± 9.2

0.194

Male: female

3 : 22

7 : 22

0.310

Symptoms during the study period

  Weakness (%)

25(100)

20(69)

0.002*

  Sensory disturbance (%)

25(100)

23(79)

0.025*

  Blurred vision (%)

25(100)

19(66)

0.001*

  Consciousness change (%)†

8(32)

1(3)

0.008*

  Diplopia (%)

2(8)

10(34)

0.025*

  Dysphagia/dysarthria (%)

0(0)

7(24)

0.012*

  Urine/stool retention (%)

12(48)

3(10)

0.003*

  Hiccup (%)

2(8)

0(0)

0.210

  Polyuria >3000 ml/day (%)

2(8)

0(0)

0.210

  Endocrinopathy (%)

7(28)

3(10)

0.160

  Diabetes mellitus (%)

3(12)

2(7)

0.653

  Thyroid dysfunction (%)

4(16)

1(3)

0.170

  Respiratory failure (%)

5(20)

0(0)

0.017*

  Expired (%)

2(8)

0(0)

0.210

Follow-up duration (months)

129.0 ± 69.5

77.6 ± 64.2

0.007*

Annual relapse rate (%)

65.0 ± 50.1

54.4 ± 47.3

0.427

AQP4 antibody (%)

25 (100)

0 (0)

0.000*

Long term steroid, IST and DMT

  Steroid

22 (88)

8 (28)

0.000*

  Steroid + Azathioprine

5 (20)

0 (0)

0.017*

  Interferon beta

2 (8)

10 (35)

0.025*

  Copaxone

1 (4)

1 (3)

1.000

  Fingolimod

0 (0)

9 (31)

0.002*

  1. NMOSD: neuromyelitis optica spectrum disorder; MS: multiple sclerosis; IST: immunosuppressant therapy; DMT: disease modifying therapy.
  2. *Statistically significant difference between NMOSD and MS.
  3. †Conscious change due to sepsis, epilepsy, shock, or other brain structure lesions.